Literature DB >> 3348238

Ulcer complications and nonsteroidal anti-inflammatory drugs.

M J Langman1.   

Abstract

Rates of ulcer perforation, hospital admission, and death are usually regarded as the best available measures of the frequency of severe peptic ulcer disease. Overall admission rates have tended to decline, which almost certainly reflects the widespread adoption of effective outpatient therapy. The overall incidence of ulcer perforation and death may also have fallen. However, at least in Europe, and in the United Kingdom in particular, there may be differences between the young and the elderly; rates of perforation and death in the young appear to be declining, whereas they are rising or static in the elderly. Although there are various interpretations for these changing patterns, data for the United Kingdom suggest that during the last 15 to 20 years some unidentified factor or factors began to influence the rates of severe peptic ulcer disease among the elderly. At least part of this change may reflect increasingly frequent prescribing of nonsteroidal anti-inflammatory drugs (NSAIDs). In the United Kingdom, most adverse drug reactions attributable to NSAIDs are gastrointestinal and are usually serious. Bleeding and perforation are common, may occur in the absence of warning symptoms, and are associated with a high mortality rate. In some countries, other factors, including smoking and diet, may be equally important. It is difficult to determine the relative contribution of each factor, though the widespread perception that the gastrointestinal tolerance of NSAIDs is poor, particularly in the elderly, may be well founded. About half the prescriptions for non-aspirin NSAIDs in the United Kingdom are for patients over 60 years of age. About one quarter of all cases of upper gastrointestinal bleeding in the elderly are likely caused by NSAIDs and are associated with a death rate of 10 percent or possibly higher. Although the absolute risk of a serious gastrointestinal complication may be low, perhaps one in several thousand NSAID prescriptions, the total burden of disease is high because of the multimillion NSAID prescriptions issued yearly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348238     DOI: 10.1016/0002-9343(88)90249-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  22 in total

Review 1.  Maximizing the safety of nonsteroidal anti-inflammatory drug use for postoperative dental pain: an evidence-based approach.

Authors:  K S Ong; R A Seymour
Journal:  Anesth Prog       Date:  2003

2.  In rheumatoid arthritis is compliance in physicians more of a problem than compliance in patients?

Authors:  R J Rooney; W W Buchanan
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  Novel anti-inflammatory activity of epoxyazadiradione against macrophage migration inhibitory factor: inhibition of tautomerase and proinflammatory activities of macrophage migration inhibitory factor.

Authors:  Athar Alam; Saikat Haldar; Hirekodathakallu V Thulasiram; Rahul Kumar; Manish Goyal; Mohd Shameel Iqbal; Chinmay Pal; Sumanta Dey; Samik Bindu; Souvik Sarkar; Uttam Pal; Nakul C Maiti; Uday Bandyopadhyay
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

Review 4.  Epidemiology of NSAID-induced gastropathy.

Authors:  H Zeidler
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

5.  Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs.

Authors:  F Díaz-González; I González-Alvaro; M R Campanero; F Mollinedo; M A del Pozo; C Muñoz; J P Pivel; F Sánchez-Madrid
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 6.  Anaesthesia in the elderly. Special considerations.

Authors:  A G Jones; J M Hunter
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

Review 7.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 8.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Cyclooxygenase inhibition with indomethacin increases human duodenal mucosal response to prostaglandin E1.

Authors:  D L Hogan; M A Ballesteros; M A Koss; J I Isenberg
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

Review 10.  From peptic ulcer disease to NSAID gastropathy. An evolving nosology.

Authors:  S H Roth
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.